Healthcare -
Medical - Devices - OTC - US
$ 1.6
8.75 %
$ 2.92 M
Market Cap
-0.06
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart TLIS
FINANCIALS
Balance Sheet
Talis Biomedical Corporation
| Current Assets | 77.7 M |
| Cash & Short-Term Investments | 76.7 M |
| Receivables | 50 K |
| Other Current Assets | 901 K |
| Non-Current Assets | 20.7 M |
| Long-Term Investments | 0 |
| PP&E | 15.4 M |
| Other Non-Current Assets | 5.21 M |
| Current Liabilities | 8.77 M |
| Accounts Payable | 1.34 M |
| Short-Term Debt | 2.88 M |
| Other Current Liabilities | 4.55 M |
| Non-Current Liabilities | 16.8 M |
| Long-Term Debt | 16.8 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Talis Biomedical Corporation
| Revenue | 412 K |
| Cost Of Revenue | 41 K |
| Gross Profit | 371 K |
| Operating Expenses | 67.2 M |
| Operating Income | -66.8 M |
| Other Expenses | -4.81 M |
| Net Income | -62 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Talis Biomedical Corporation
| Net Income | -62 M |
| Depreciation & Amortization | 770 K |
| Capital Expenditures | -486 K |
| Stock-Based Compensation | 4.35 M |
| Change in Working Capital | -3.42 M |
| Others | 5.82 M |
| Free Cash Flow | -53.7 M |
Wall Street Analysts Price Targets
Talis Biomedical Corporation
TLIS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
TLIS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Talis Biomedical Corporation
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
103 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
North American Morning Briefing : Global Ad Shares -2-
Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon Closing; To Also Get up to $150M in Contingent Cash Upon Satisfaction of Condition; Proceeds Will Strengthen Balance Sheet and Support Growth Plans in the Vicuña District Expected Major Events for Monday aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); 00:01/UK: Nov KPMG and REC UK Report on Jobs 04:30/JPN: Nov Corporate Insolvencies 05:00/JPN: Nov Economy Watchers Survey 07:00/GER: 3Q Labour cost index 15:00/US: Oct Monthly Wholesale Trade 15:00/US: Nov Employment Trends Index 23:50/JPN: Nov Money Stock, Broadly-defined Liquidity All times in GMT. Powered by Kantar Media and Dow Jones. Expected Earnings for Monday Amtech Systems Inc (ASYS) is expected to report $-0.01 for 4Q. Anavex Life Sciences Corp (AVXL) is expected to report $-0.16 for 4Q. Avalon Advanced Materials is expected to report for 4Q. Braze Inc (BRZE) is expected to report $-0.30 for 3Q. Buckle Inc (BKE) is expected to report. C3.ai Inc (AI) is expected to report $-0.60 for 2Q. Casey's General Stores Inc (CASY) is expected to report $4.25 for 2Q. Centene Corp (CNC) is expected to report for Full year. Digital Ally Inc (DGLY) is expected to report for 3Q. Franklin Resources Inc (BEN) is expected to report. Genasys Inc (GNSS) is expected to report $-0.11 for 4Q. Healthequity Inc (HQY) is expected to report $0.24 for 3Q. MongoDB Inc (MDB) is expected to report $-0.83 for 3Q. NexPoint Diversified Real Estate Trust (NXDT) is expected to report for 3Q. North West Co Inc (NWC.T) is expected to report $0.77 for 3Q. Oil-Dri Corp of America (ODC) is expected to report for 1Q. Oracle Corp (ORCL) is expected to report $1.06 for 2Q. Phreesia Inc (PHR) is expected to report $-0.27 for 3Q. Planet Labs PBC (PL) is expected to report $-0.08 for 3Q. Remark Holdings Inc (MARK) is expected to report $-0.19 for 3Q. Rent the Runway Inc (RENT) is expected to report for 3Q. Smart Share Global Ltd - ADR (EM) is expected to report for 3Q. Talis Biomedical Corp (TLIS) is expected to report for 3Q. Titan Pharmaceuticals Inc (TTNP) is expected to report for 3Q. Toll Brothers Inc (TOL) is expected to report $4.34 for 4Q. Vail Resorts (MTN) is expected to report $-4.96 for 1Q. VersaBank is expected to report $0.29 for 4Q. Webco Industries Inc (WEBC) is expected to report for 1Q. Yext Inc (YEXT) is expected to report $0.06 for 3Q. Powered by Kantar Media and Dow Jones. ANALYST RATINGS ACTIONS Altria Raised to Buy From Neutral by B of A Securities Argan Cut to Market Perform From Market Outperform by CJS Securities Asana Raised to Sector Weight From Underweight by Keybanc Brixmor Property Group Raised to Outperform From Market Perform by BMO Capital Deere & Co Cut to Hold From Buy by Jefferies DocuSign Cut to Reduce From Hold by HSBC Dollar General Raised to Buy From Underperform by B of A Securities Duckhorn Portfolio Cut to Hold From Buy by Jefferies EPAM Systems Raised to Buy From Neutral by Goldman Sachs Fortrea Holdings Cut to Neutral From Outperform by Baird GrafTech International Raised to Neutral From Underweight by JP Morgan Hewlett Packard Ent Raised to Buy From Neutral by Citigroup Kennametal Cut to Hold From Buy by Jefferies Molson Coors Beverage Raised to Buy From Neutral by B of A Securities ONE Gas Cut to Neutral From Buy by Ladenburg Thalmann Paccar Cut to Hold From Buy by Jefferies Peloton Interactive Raised to Neutral From Sell by UBS PJT Partners Raised to Neutral From Sell by UBS PotlatchDeltic Raised to Outperform From Market Perform by BMO Capital ProFrac Holding Cut to Underweight From Neutral by JP Morgan Prologis Cut to Underperform From Market Perform by BMO Capital ProPetro Holding Raised to Neutral From Underweight by JP Morgan Republic Services Raised to Outperform From Market Perform by BMO Capital Robinhood Markets Raised to Buy From Neutral by Goldman Sachs SiteOne Landscape Supply Raised to Buy From Hold by Jefferies Smith & Wesson Brands Cut to Hold From Buy by Craig-Hallum Smith & Wesson Brands Cut to Hold From Buy by Lake Street Timken Raised to Buy From Hold by Jefferies WesBanco Raised to Strong Buy From Outperform by Raymond James Weyerhaeuser Raised to Outperform From Market Perform by BMO Capital This article is a text version of a Wall Street Journal newsletter published earlier today. (END) Dow Jones Newswires 12-09-24 0634ET
https://www.marketscreener.com
- 5 months ago
Why Is Talis Biomedical (TLIS) Stock Down 52% Today?
Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.
investorplace.com
- 9 months ago
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions.
globenewswire.com
- 1 year ago
7 Small-Cap Stocks to Sell in August Before They Crash and Burn
Although speculative enterprises tend to draw in a loyal band of followers, certain circumstances call for decisive action, as these small-cap stocks to avoid in August confirms. Nobody wants to be the guy or gal throwing in the towel.
investorplace.com
- 1 year ago
Talis Biomedical Corporation (TLIS) Q2 2023 Earnings Call Transcript
Talis Biomedical Corporation (NASDAQ:TLIS ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical Second Quarter Results and Business Update Conference Call.
seekingalpha.com
- 1 year ago
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.
globenewswire.com
- 1 year ago
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
globenewswire.com
- 1 year ago
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.
globenewswire.com
- 1 year ago
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In order to regain compliance, the Company's common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days which the Company satisfied on July 19, 2023. Accordingly, the Notice stated that Nasdaq now considers the matter closed.
globenewswire.com
- 1 year ago
Talis Biomedical Corporation (TLIS) Q1 2023 Earnings Call Transcript
Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call.
seekingalpha.com
- 2 years ago
Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
globenewswire.com
- 2 years ago
Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO
PRESS RELEASE: INSIDE INFORMATION/ REGULATED INFORMATION11 April 2023, 22:00 CEST Biocartis appoints Roger Moody as new CEO Roger Moody to be a ppointed as new Chief Executive Officer and member of the Board of Directors Herman Verrelst , current Chief Executive Officer , will move into the position of Executive Chairman of the Board of Directors Addit ional extensive experience in the US diagnostic market while leveraging existing knowledge and relationships Mechelen, Belgium, 11 April 202 3 - Biocartis Group NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces changes to its executive management. Roger Moody has been appointed to the position of Chief Executive Officer effective 24 April 2023.
globenewswire.com
- 2 years ago
8. Profile
Summary
Talis Biomedical Corporation TLIS
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 2.92 M
Dividend Yield
0.00%
Description
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Contact
230 Constitution Drive, Menlo Park, CA, 94025
https://talisbio.com
IPO
Date
Feb. 12, 2021
Employees
99
Officers
Gillian Green
Company Secretary
Ms. Margaret Barrett M.S.
Controller
Ms. Rebecca Markovich
Interim Chief Financial Officer